The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

CDC staff received an email this week telling them to avoid using more than a dozen terms or words-- including "health equity ...

Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

Neurodevelopmental disorders company GRIN Therapeutics, an affiliate of the Blackstone Life Sciences portfolio company ...

Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

Recent research has highlighted the significant role of Omega-3 fatty acids in supporting heart health, including some ...

Cision, a global leader in media intelligence and communications solutions, in partnership with PRWeek, today announced the ...

Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...